Likewise, the influence of hyperglycemia in PET scans of diabetic cancer patients [56] can be mitigated by the acceleration of glucosuria [57] with the use of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, which may incur hypoglycemia risk. Here, SLC5A2 is linked to cancer.